Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus

Published:2010-12 Issue:12 Volume:85 Page:S38-S49
ISSN:0025-6196
Container-title:Mayo Clinic Proceedings
language:en
Short-container-title:Mayo Clinic Proceedings

Author:

Unger Jeff

Publisher

Elsevier BV

Subject

General Medicine

Reference81 articles.

1. Introduction;Unger,2007

2. Appropriate, timely, and rational treatment of type 2 diabetes mellitus: meeting the challenges of primary care;Unger;Insulin,2009

3. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007;Centers for Disease Control and Prevention (CDC),2008

4. National trends in treatment of type 2 diabetes mellitus, 1994-2007;Alexander;Arch Intern Med,2008

5. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes;Nathan;Diabetes Care,2009

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Redesigning Diabetes Care for Treatment Inertia: A Population Health Model;Population Health Management;2024-04-01

2. Do Financial Incentives Affect Utilization for Chronically Ill Medicare Beneficiaries?;Medical Care;2022-02-25

3. GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes;Endocrinology and Diabetes;2022

4. Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care ( LIRA‐PRIME );Diabetes, Obesity and Metabolism;2021-10-18

5. Synthesis, molecular docking and ADMET prediction of novel swertiamarin analogues for the restoration of type-2 diabetes: an enzyme inhibition assay;Natural Product Research;2020-10-01